文献速递骨软组织肉瘤与黑色素瘤

早期黑色素瘤微转移的国际多中心研究:临床结局与风险分层——对美国癌症联合委员会IIIA期疾病管理的启示

Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.
PubMed 文献 · J Clin Oncol · 2022-07-18

PURPOSE: Indications for offering adjuvant systemic therapy for patients with early-stage melanomas with low disease burden sentinel node (SN) micrometastases, namely, American Joint Committee on Cancer (AJCC; eighth edition) stage IIIA disease, are presently controversial.…

要点

  • 前哨淋巴结转移灶最大径0.3 mm是AJCC IIIA期黑色素瘤的最佳生存分层切点。
  • 转移灶≥0.3 mm者5年疾病特异性生存率80.3%,<0.3 mm者94.1%(HR 1.26,P<.0001)。
  • 转移灶<0.3 mm的AJCC IIIA患者生存与AJCC IB患者无差异。

核心结论

  • AJCC IIIA期黑色素瘤伴前哨淋巴结转移灶最大径≥0.3 mm者疾病进展风险较高,可能从辅助全身治疗或临床试验入组中获益。
  • 前哨淋巴结转移灶最大径<0.3 mm者可参照前哨淋巴结阴性AJCC IB患者管理,从而避免常规影像学监测和更密集随访。

研究设计与样本

  • 研究为来自澳大利亚、欧洲、北美九个高容量癌症中心组成的洲际联盟的成人患者队列。
  • 纳入2005年至2020年间接受前哨淋巴结活检的病理分期pT1b/pT2a原发性皮肤黑色素瘤患者。
  • 分析患者数据、原发肿瘤和前哨淋巴结特征及生存结局。

主要发现

  • 配对疾病比较显示N1a与N2a亚组间无显著生存差异。
  • 生存分析确定前哨淋巴结肿瘤沉积最大径0.3 mm为分层生存的最佳切点。
  • 总体无病生存和远处无转移生存也观察到类似结果。
  • AJCC IB期患者与低风险(<0.3 mm)AJCC IIIA期患者间无生存差异。

关键数值与推荐

  • 新识别的高风险(≥0.3 mm)亚组占AJCC IIIA期队列的271例(66.4%)。
  • 仅142例(34.8%)患者前哨淋巴结肿瘤沉积最大径>1 mm。

临床怎么用

  • 作者认为,AJCC IIIA期黑色素瘤伴前哨淋巴结转移灶最大径≥0.3 mm者可能从辅助全身治疗或临床试验入组中获益。
  • 作者认为,前哨淋巴结转移灶最大径<0.3 mm者可参照前哨淋巴结阴性AJCC IB患者管理,避免常规影像学监测和更密集随访。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Indications for offering adjuvant systemic therapy for patients with early-stage melanomas with low disease burden sentinel node (SN) micrometastases, namely, American Joint Committee on Cancer (AJCC; eighth edition) stage IIIA disease, are presently controversial. The current study sought to identify high-risk SN-positive AJCC stage IIIA patients who are more likely to derive benefit from adjuvant systemic therapy. METHODS: Patients were recruited from an intercontinental (Australia/Europe/North America) consortium of nine high-volume cancer centers. All were adult patients with pathologic stage pT1b/pT2a primary cutaneous melanomas who underwent SN biopsy between 2005 and 2020. Patient data, primary tumor and SN characteristics, and survival outcomes were analyzed. RESULTS: Three thousand six hundred seven patients were included. The median follow-up was 34 months. Pairwise disease comparison demonstrated no significant survival difference between N1a and N2a subgroups. Survival analysis identified a SN tumor deposit maximum dimension of 0.3 mm as the optimal cut point for stratifying survival. Five-year disease-specific survival rates were 80.3% and 94.1% for patients with SN metastatic tumor deposits ≥ 0.3 mm and < 0.3 mm, respectively (hazard ratio, 1.26 [1.11 to 1.44]; P < .0001). Similar findings were seen for overall disease-free and distant metastasis-free survival. There were no survival differences between the AJCC IB patients and low-risk (< 0.3 mm) AJCC IIIA patients. The newly identified high-risk (≥ 0.3 mm) subgroup comprised 271 (66.4%) of the AJCC IIIA cohort, whereas only 142 (34.8%) patients had SN tumor deposits > 1 mm in maximum dimension. CONCLUSION: Patients with AJCC IIIA melanoma with SN tumor deposits ≥ 0.3 mm in maximum dimension are at higher risk of disease progression and may benefit from adjuvant systemic therapy or enrollment into a clinical trial. Patients with SN deposits < 0.3 mm in maximum dimension can be managed similar to their SN-negative, AJCC IB counterparts, thereby avoiding regular radiological surveillance and more intensive follow-up.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Moncrieff MD, Lo SN, Scolyer RA, et al. Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease. J Clin Oncol. 2022. PMID: 35849790. doi:10.1200/JCO.21.02488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。